H.C. Wainwright Thinks Genocea Biosciences’ Stock is Going to Recover

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Genocea Biosciences (GNCAResearch Report) today and set a price target of $9.00. The company’s shares closed last Thursday at $1.16, close to its 52-week low of $0.85.

According to, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -21.2% and a 24.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Genocea Biosciences with a $7.67 average price target.

See today’s best-performing stocks on TipRanks >>

Based on Genocea Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.64 million and GAAP net loss of $3.62 million. In comparison, last year the company earned revenue of $453K and had a GAAP net loss of $4.56 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

Read More on GNCA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed